QQQ   441.81 (-0.80%)
AAPL   177.96 (+1.67%)
MSFT   424.67 (-0.76%)
META   516.25 (-1.32%)
GOOGL   159.87 (+0.29%)
AMZN   188.15 (-0.48%)
TSLA   172.19 (-1.38%)
NVDA   894.21 (-1.32%)
AMD   163.00 (-4.40%)
NIO   4.17 (-6.50%)
BABA   72.58 (-3.03%)
T   16.39 (-0.18%)
F   12.78 (-1.99%)
MU   125.00 (-1.97%)
GE   156.07 (-0.84%)
CGC   8.10 (-0.61%)
DIS   115.64 (-1.29%)
AMC   2.76 (-1.43%)
PFE   26.21 (-0.49%)
PYPL   65.51 (-0.44%)
XOM   123.32 (+1.26%)
QQQ   441.81 (-0.80%)
AAPL   177.96 (+1.67%)
MSFT   424.67 (-0.76%)
META   516.25 (-1.32%)
GOOGL   159.87 (+0.29%)
AMZN   188.15 (-0.48%)
TSLA   172.19 (-1.38%)
NVDA   894.21 (-1.32%)
AMD   163.00 (-4.40%)
NIO   4.17 (-6.50%)
BABA   72.58 (-3.03%)
T   16.39 (-0.18%)
F   12.78 (-1.99%)
MU   125.00 (-1.97%)
GE   156.07 (-0.84%)
CGC   8.10 (-0.61%)
DIS   115.64 (-1.29%)
AMC   2.76 (-1.43%)
PFE   26.21 (-0.49%)
PYPL   65.51 (-0.44%)
XOM   123.32 (+1.26%)
QQQ   441.81 (-0.80%)
AAPL   177.96 (+1.67%)
MSFT   424.67 (-0.76%)
META   516.25 (-1.32%)
GOOGL   159.87 (+0.29%)
AMZN   188.15 (-0.48%)
TSLA   172.19 (-1.38%)
NVDA   894.21 (-1.32%)
AMD   163.00 (-4.40%)
NIO   4.17 (-6.50%)
BABA   72.58 (-3.03%)
T   16.39 (-0.18%)
F   12.78 (-1.99%)
MU   125.00 (-1.97%)
GE   156.07 (-0.84%)
CGC   8.10 (-0.61%)
DIS   115.64 (-1.29%)
AMC   2.76 (-1.43%)
PFE   26.21 (-0.49%)
PYPL   65.51 (-0.44%)
XOM   123.32 (+1.26%)
QQQ   441.81 (-0.80%)
AAPL   177.96 (+1.67%)
MSFT   424.67 (-0.76%)
META   516.25 (-1.32%)
GOOGL   159.87 (+0.29%)
AMZN   188.15 (-0.48%)
TSLA   172.19 (-1.38%)
NVDA   894.21 (-1.32%)
AMD   163.00 (-4.40%)
NIO   4.17 (-6.50%)
BABA   72.58 (-3.03%)
T   16.39 (-0.18%)
F   12.78 (-1.99%)
MU   125.00 (-1.97%)
GE   156.07 (-0.84%)
CGC   8.10 (-0.61%)
DIS   115.64 (-1.29%)
AMC   2.76 (-1.43%)
PFE   26.21 (-0.49%)
PYPL   65.51 (-0.44%)
XOM   123.32 (+1.26%)
NASDAQ:BIOL

BIOLASE (BIOL) Stock Price, News & Analysis

$0.14
-0.01 (-3.48%)
(As of 09:57 AM ET)
Today's Range
$0.14
$0.15
50-Day Range
$0.13
$0.70
52-Week Range
$0.13
$47.10
Volume
433,929 shs
Average Volume
4.93 million shs
Market Capitalization
$4.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$77.00

BIOLASE MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
53,298.1% Upside
$77.00 Price Target
Short Interest
Bearish
7.46% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of BIOLASE in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.39 out of 5 stars

BIOL stock logo

About BIOLASE Stock (NASDAQ:BIOL)

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

BIOL Stock Price History

BIOL Stock News Headlines

BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Analysts Predict Price Tag for Gold to TRIPLE
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Why BIOLASE Shares Are Surging Friday
Q4 2023 BIOLASE Inc Earnings Call
Recap: Biolase Q4 Earnings
Biolase: Q4 Earnings Snapshot
Earnings Preview For Biolase
Maxim Group Reaffirms Their Buy Rating on Biolase (BIOL)
See More Headlines
Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/11/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Dental equipment & supplies
Sub-Industry
N/A
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
Employees
157
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$77.00
High Stock Price Target
$150.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+51,439.5%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-20,630,000.00
Pretax Margin
-41.90%

Debt

Sales & Book Value

Annual Sales
$49.16 million
Book Value
($0.07) per share

Miscellaneous

Free Float
32,520,000
Market Cap
$4.86 million
Optionable
Not Optionable
Beta
0.67
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives


BIOL Stock Analysis - Frequently Asked Questions

What is BIOLASE's stock price target for 2024?

0 brokers have issued 12-month target prices for BIOLASE's shares. Their BIOL share price targets range from $4.00 to $150.00. On average, they predict the company's stock price to reach $77.00 in the next twelve months. This suggests a possible upside of 53,298.1% from the stock's current price.
View analysts price targets for BIOL
or view top-rated stocks among Wall Street analysts.

How have BIOL shares performed in 2024?

BIOLASE's stock was trading at $1.1220 on January 1st, 2024. Since then, BIOL stock has decreased by 87.1% and is now trading at $0.1442.
View the best growth stocks for 2024 here
.

When is BIOLASE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BIOL earnings forecast
.

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) posted its quarterly earnings results on Wednesday, November, 10th. The medical technology company reported ($50.00) earnings per share for the quarter, topping analysts' consensus estimates of ($75.00) by $25.00. The medical technology company had revenue of $9.53 million for the quarter. BIOLASE had a negative net margin of 41.97% and a negative trailing twelve-month return on equity of 555.22%. During the same quarter in the prior year, the firm earned ($525.00) EPS.

When did BIOLASE's stock split?

BIOLASE shares reverse split on the morning of Friday, July 28th 2023. The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE issued an update on its first quarter 2024 earnings guidance on Thursday, March, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10.0 million-, compared to the consensus revenue estimate of $10.8 million.

What is John R. Beaver's approval rating as BIOLASE's CEO?

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?
How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BIOL) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners